CANN GROUP LIMITED — AGM Information 2022

Oct 24, 2022

==> picture [109 x 42] intentionally omitted <==

ASX ANNOUNCEMENT

25 October 2022

AGM Presentation

25 October 2022 – In advance of this morning’s Annual General Meeting of shareholders to be held at 10:00am, and in accordance with ASX Listing Rule 3.13.3, Cann Group Limited (CAN:ASX) is pleased to provide a copy of the presentation that will be made to shareholders at the AGM.

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Rhys Cohen Senior Corporate Communications Manager +61 449 679 095 rhys.cohen@canngrouplimited.com

For all other information please contact:

Peter Crock Deborah Ambrosini CEO CFO Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 contact@canngrouplimited.com deborah.ambrosini@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. Learn more at: www.canngrouplimited.com | www.satipharm.com

Cann Group Limited (ACN 603 949 739) 262-276 Lorimer Street, Port Melbourne VIC 3207 Australia Ph: +61 3 9095 7088

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Annual General Meeting

25 October 2022

Cann Group Limited ABN 25 603 949 739

Disclaimer | Important notice

This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann).

Summary information

This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentation. The information provided in this Presentation pertaining to Cann and its business assets, strategy and operations is for general informational purposes only.

Future performance

This Presentation contains certain ‘forward looking statements’, including but not limited to projections, guidance on future revenues and other potential synergies and estimates about the future performance of Cann. Forward looking statements can generally be identified by the use of forward-looking words such as, ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’ ‘outlook’, ‘guidance’, ‘potential’ and other similar expressions within the meaning of securities laws of applicable jurisdictions.

The forward-looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Cann, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Cann). There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to Cann as at the date of this Presentation.

Except as required by law or regulation (including the ASX Listing Rules), Cann undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Past performance

Investors should note that past performance, including any historical information in this Presentation cannot be relied upon as an indicator of (and provides no guidance as to) future Cann performance including future share price performance.

All rights reserved

Copyright in this Presentation (including in any photographs) is the property of or is licensed to Cann and is protected under copyright laws. No part of this Presentation may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the Company, except in the case of brief quotations embodied in critical reviews and certain other non-commercial uses permitted by copyright law.

==> picture [106 x 41] intentionally omitted <==

2 |

Agenda

Introduction

Enhancing patients’ lives by developing, producing and supplying innovative cannabis medicines.

1

Chairman’s Address

2

CEO’s Address

3 Q&A 4

Formal Business of AGM

5 Meetin Close g

==> picture [162 x 55] intentionally omitted <==

----- Start of picture text -----

|
----- End of picture text -----

6

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

1 General Meeting

4

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

2 Chairman’s Address

Mr Allan McCallum, AO

5

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Corporate Growth

6

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Market Growth

7

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Satipharm

8

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Share Purchase Plan

9

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Board and Management Changes

10

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

3 CEO’s Address

Mr Peter Crock

11

==> picture [641 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Mildura

12

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Commercial Focus

13

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Satipharm

14

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Share Purchase Plan

15

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

Outlook

16

THIS SLIDE APPEARS IN PLACE OF A VIDEO

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

4 Q&A

18

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

5 Formal Business of AGM

19

Item 1 | Financial statements and reports

To receive the financial report, directors’ report and auditor’s report for the Company and its controlled entities for the financial year ended 30 June 2022.

==> picture [1440 x 94] intentionally omitted <==

----- Start of picture text -----

20 |
----- End of picture text -----

==> picture [642 x 810] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

6 Resolutions for Voting

21

Resolution 1 | Adoption of the Remuneration Report

That pursuant to and in accordance with section 250R(2) of the Corporations Act, the Remuneration Report for the financial year ending 30 June 2022 as set out in pages 28 to 35 (inclusive) of the Annual Report be adopted.

Proxyvotes
	For	Open	Against	Total valid available votes	% of issued capital	Abstain
Votes	21,265,060	1,096,743	1,331,793	23,693,596	6.74%	42,793
Percentage	89.75%	4.63%	5.62%

==> picture [1440 x 94] intentionally omitted <==

----- Start of picture text -----

22 |
----- End of picture text -----

Resolution 2 | Re-election of Director

That Mr Allan McCallum, AO, a Director who retires from office in accordance with ASX Listing Rule 14.4 and Rule 50.2 of the Company’s Constitution and being eligible for re-election, be re-elected a Director of the Company.

Proxyvotes
	For	Open	Against	Total valid available votes	% of issued capital	Abstain
Votes	26,115,026	1,211,890	572,605	27,899,521	7.94%	195,729
Percentage	93.60%	4.34%	2.05%

==> picture [1440 x 94] intentionally omitted <==

----- Start of picture text -----

23 |
----- End of picture text -----

Resolution 3 | Re-election of Director

That Mr Robert Barnes, a Director who was appointed to fill a casual vacancy with Rule 49.1 of the Company’s Constitution until this Annual General Meeting in accordance with ASX Listing Rule 14.4 and being eligible for re-election, be reelected a Director of the Company.

Proxyvotes
	For	Open	Against	Total valid available votes	% of issued capital	Abstain
Votes	32,792,164	1,195,524	602,953	34,590,641	9.84%	205,064
Percentage	94.80%	3.46%	1.74%

==> picture [1440 x 94] intentionally omitted <==

----- Start of picture text -----

24 |
----- End of picture text -----

Resolution 4 | Ratification of prior issue of shares

That, for the purpose of Listing Rule 7.4, Shareholders ratify the prior issue of 254,687 ordinary shares issued to Commonwealth Scientific and Industrial Research Organisation as set out in the Explanatory Memorandum which accompanies and forms part of the Notice of this Meeting.

Proxyvotes
	For	Open	Against	Total valid available votes	% of issued capital	Abstain
Votes	30,418,041	1,096,155	1,185,756	32,699,952	9.31%	165,533
Percentage	93.02%	3.35%	3.63%

==> picture [1440 x 94] intentionally omitted <==

----- Start of picture text -----

25 |
----- End of picture text -----

Resolution 5 | Approval of additional 10% placement capacity for 12 months

That, for the purpose of Listing Rule 7.1A, approval is given for the issue of equity securities, as that term is defined in the Listing Rules, totalling up to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2.

Proxyvotes
	For	Open	Against	Total valid available votes	% of issued capital	Abstain
Votes	30,473,502	1,094,045	3,044,733	34,612,280	9.85%	183,425
Percentage	88.04%	3.16%	8.80%

==> picture [1440 x 94] intentionally omitted <==

----- Start of picture text -----

26 |
----- End of picture text -----

==> picture [1440 x 294] intentionally omitted <==

Contact

Peter Crock

Chief Executive Officer

peter.crock@canngrouplimited.com

Deborah Ambrosini

Chief Financial Officer

deborah.ambrosini@canngrouplimited.com

Rhys Cohen

Senior Corporate Communications Manager rhys.cohen@canngrouplimited.com

==> picture [143 x 56] intentionally omitted <==

canngrouplimited.com | +61 3 9095 7188